The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF THE MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGITEC(REGISTERED) VACCINE OR ONE DOSE OF THE MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 1-10 YEAR OLD SUBJECTS WITH MENACWY-TT, MENINGITEC(REGISTERED) OR MENCEVAX(REGISTERED) ACWY.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01962207

Enrollment

243

Registered

2013-10-14

Start date

2013-10-31

Completion date

2018-06-30

Last updated

2019-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Meningococcal

Keywords

10 years Meningitec, Safety, booster response, Adolescents, Adults, Immunogenicity, Mencevax ACWY

Brief summary

The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10 years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ or Mencevax™ ACWY, and the safety and immunogenicity of a booster dose of MenACWY-TT administered 10 years after the primary vaccination. All subjects received a primary vaccination at 1 to 10 years of age in study 108658 (NCT00427908). No new subjects will be enrolled in this booster study.

Detailed description

The study aims to evaluate the antibody persistence post primary vaccination with active control, safety and immunogenicity of a booster dose uncontrolled post primary vaccination during different phases: Persistence phase: Long-term persistence 6, 7, 8, 9 and 10 years after primary vaccination with MenACWY-TT or Meningitec or Mencevax ACWY, in study MenACWY-TT-027. Booster phase: One month post booster vaccination with MenACWY-TT vaccine ten years after primary vaccination. The subjects in this study will be allocated to the same groups as in the vaccination study MenACWY-TT-027 (NCT00427908).

Interventions

BIOLOGICALMeningococcal vaccine GSK134612

One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Subjects and/or subjects' parent(s)/Legally Acceptable Representative(s) (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * A male or female who has received a primary vaccination with the MenACWY-TT, Meningitec or Mencevax ACWY vaccines in study MenACWY-TT-027 (NCT00427908). * In alignment with local laws and regulations, written informed consent obtained from parents/LAR(s) of the subject and written informed assent obtained from the subject if the subject is less than 15 years of age, or written informed consent obtained from the subject if the subject has achieved the 15th birthday. The subjects ≥15 years of age at the time of enrollment will sign the informed consent form, even if the parent/ LAR previously signed the ICF before the subject reached the legal age of consent. * Healthy subjects as established by medical history and history-directed physical examination before entering into the study. All subjects must satisfy the following additional criteria prior to entry of the booster phase: * Female subjects of non-childbearing potential may be enrolled in the study. * Non-childbearing potential is defined as pre-menarche, hysterectomy or bilateral ovariectomy. * Male subjects able to father children and female subjects of childbearing potential (including females who have had tubal ligation) and at risk of pregnancy may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccination (for females only), and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination.

Exclusion criteria

* Child in care. * Previous vaccination with meningococcal polysaccharide or conjugate vaccine outside of study MenACWY-TT-027. Note: Subjects who were revaccinated with a monovalent MenC conjugate vaccine because of suboptimal response during the persistence phase of the MenACWY-TT-027 study (i.e. MenACWY-TT-028, -029, -030, -031 and -032) are allowed to participate as they will be followed for the persistence of MenA, MenW-135 and MenY. * History of meningococcal disease due to serogroup A, C, W-135 or Y. * Previous vaccination with meningococcal B vaccine. * Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including Human Immunodeficiency Virus (HIV) infection, based on medical history and physical examination (no laboratory testing required). * Family history of congenital or hereditary immunodeficiency. * Major congenital defects or serious chronic illness. * History of chronic alcohol consumption and/or drug abuse. * Subjects who withdrew consent to be contacted for follow-up studies. Additional

Design outcomes

Primary

Measure	Time frame	Description
Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	9 years after primary vaccination (Year 4 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	10 years after primary vaccination (Year 4 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	6 years after primary vaccination (Year 1 of study MENACWY-TT-100)	Serogroups included Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY).
Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	7 years after primary vaccination (Year 2 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	8 years after primary vaccination (Year 3 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	6 Years after primary vaccination (Year 1 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	7 years after primary vaccination (Year 2 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	8 years after primary vaccination (Year 3 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	9 years after primary vaccination (Year 4 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	10 years after primary vaccination (Year 5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.

Secondary

Measure	Time frame	Description
Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination	Up to 31 days post booster vaccination	An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination	Up to 6 months post booster vaccination	New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.
Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination	Up to 6 months post booster vaccination	An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY. rSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: rSBA antibody titer \>= 1:32 one month after vaccination, and at least 4-fold increase in rSBA titers one month after vaccination.
Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY.
Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)	Serogroups included MenA, MenC, MenW-135 and MenY. hSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: hSBA antibody titer \>= 1:8 one month after vaccination, and at least 4-fold increase in hSBA titers one month after vaccination.
Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy	Through 5 years (6, 7, 8, 9 and 10 years post primary vaccination)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs related to lack of vaccine efficacy were as judged by the investigator.
Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Up to 4 days post booster vaccination	Solicited general events: fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea and/or abdominal pain, headache (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe/prevented normal activity) and fever (\>=37.5°C for oral/axillary/tympanic route, \>=38.0°C for rectal route). Solicited local events: pain (0=none, 1=mild, not interfered/prevented normal activity, 2=moderate, painful when limb moved/interfered with normal activity, 3=severe, significant pain at rest/prevented normal activity), redness and swelling at injection site (record greatest surface diameter in millimeter (mm) as 0 to \<=20 mm, \>20 to \<=50 mm, \>50 mm). Participants may be represented in more than 1 category. Only categories with at least 1 participant reported. 'Medical advice' signifies medical advice received to resolve any event. 'Related'=relationship to study vaccine assessed by investigator.

Countries

Finland

Participant flow

Pre-assignment details

In this study, participants from the study MENACWY-TT-027 \[NCT00427908\] were followed up for assessment of persistence of immune response and safety. And those who consented received booster vaccination and were followed up for another 6 months.

Participants by arm

Arm	Count
MenACWY-TT Vaccine: Less Than (<) 2 Years Persistence phase was followed up by booster phase. Persistence phase: Participants with \<2 years of age, received a single 0.5 milliliter (mL) dose of meningococcal serogroups A, C, W 135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100), they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.	76
MenCCRM (Meningitec) Vaccine: Less Than 2 Years Persistence phase was followed up by booster phase. Persistence phase: Participants with \<2 years of age, received a single 0.5 mL dose of Meningitec vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.	23
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years Persistence phase was followed up by booster phase. Persistence phase: Participants with \>=2 years of age, received a single 0.5 mL dose of MenACWY-TT vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long-term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.	115
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years Persistence phase was followed up by booster phase. Persistence phase: Participants with \<2 years of age, received a single 0.5 mL dose of MencevaxACWY vaccine intramuscularly, as primary vaccination in study MENACWY-TT-027. Then, in this study (MENACWY-TT-100) they were evaluated for long term persistence (of immune response and safety) for 5 years (6, 7, 8, 9 and 10 years post primary vaccination). Booster phase: Participants who provided consent, received a single 0.5 mL booster dose of MenACWY-TT vaccine intramuscularly in this study, 10 years post primary vaccination in MENACWY-TT-027, and were followed up for 6 months after booster vaccination.	29
Total	243

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Persistence Phase (5 Years)	Adverse Event	0	0	1	0
Persistence Phase (5 Years)	Eligibility criteria not fulfilled	0	0	3	1
Persistence Phase (5 Years)	Lost to Follow-up	2	1	5	2
Persistence Phase (5 Years)	Migrated/moved from study area	2	0	4	0
Persistence Phase (5 Years)	Missed at least 1 persistence visit	21	7	13	5
Persistence Phase (5 Years)	Withdrawal by Subject	4	5	18	4

Baseline characteristics

Characteristic	Total	MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	MenCCRM (Meningitec) Vaccine: Less Than 2 Years	MenACWY-TT Vaccine: Less Than (<) 2 Years
Age, Continuous	10.7 years STANDARD_DEVIATION 3	12.1 years STANDARD_DEVIATION 2.9	12.5 years STANDARD_DEVIATION 2.6	8.2 years STANDARD_DEVIATION 0.7	8.2 years STANDARD_DEVIATION 0.7
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	243 Participants	29 Participants	115 Participants	23 Participants	76 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Other	4 Participants	1 Participants	1 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized White - Arabic/North African heritage	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized White - Caucasian/European heritage	238 Participants	28 Participants	113 Participants	22 Participants	75 Participants
Sex: Female, Male Female	122 Participants	14 Participants	56 Participants	12 Participants	40 Participants
Sex: Female, Male Male	121 Participants	15 Participants	59 Participants	11 Participants	36 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk
deaths Total, all-cause mortality	0 / 76	0 / 23	0 / 115	0 / 29	0 / 67	0 / 16	0 / 77	0 / 21
other Total, other adverse events	0 / 76	0 / 23	0 / 115	0 / 29	53 / 67	12 / 16	65 / 77	15 / 21
serious Total, serious adverse events	0 / 76	0 / 23	0 / 115	0 / 29	0 / 67	0 / 16	1 / 77	0 / 21

Outcome results

Primary

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 10 years after primary vaccination (Year 5 of study MENACWY-TT-100)

Population: All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027, had available assay results for at least 1 tested antigen. N: number of participants evaluable for this measure. Number analyzed: participants analyzed for specified serogroup.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA	29.3 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC	132.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135	16.7 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY	25.8 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC	81.7 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135	4.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY	22.2 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA	5.8 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135	187.2 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC	175.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY	90.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA	106.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY	12.7 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC	105.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA	9.1 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135	14.0 titers

Primary

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 6 Years after primary vaccination (Year 1 of study MENACWY-TT-100)

Population: All eligible participants who received primary vaccination with MenACWY-TT, Meningitec or Mencevax ACWY in Study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. N: number of participants evaluable for this measure.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA	16.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC	161.3 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135	18.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY	21.5 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC	103.1 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135	6.2 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY	21.7 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA	5.9 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135	265.2 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC	192.9 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY	136.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA	107.3 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY	11.6 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC	98.7 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA	5.8 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135	7.6 titers

Primary

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 7 years after primary vaccination (Year 2 of study MENACWY-TT-100)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY	19.9 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC	104.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135	13.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA	20.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC	54.3 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA	6.1 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY	18.3 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135	6.8 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA	65.3 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC	139.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY	152.7 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135	206.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA	7.4 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135	6.3 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC	101.6 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY	8.2 titers

Primary

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 8 years after primary vaccination (Year 3 of study MENACWY-TT-100)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA	15.8 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC	110.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135	15.3 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY	26.1 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC	64.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135	6.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY	33.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA	4.8 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135	252.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC	140.1 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY	181.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA	51.3 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY	10.9 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC	121.1 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA	7.8 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135	11.8 titers

Primary

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 9 years after primary vaccination (Year 4 of study MENACWY-TT-100)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC	166.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY	23.1 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135	17.3 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA	28.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY	32.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA	5.2 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC	92.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135	6.6 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC	176.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135	274.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA	118.8 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY	106.2 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA	10.9 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC	164.3 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY	10.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135	9.7 titers

Primary

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 10 years after primary vaccination (Year 4 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:8	65.6 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	28.1 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:28	26.6 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:28	64.1 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:8	82.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:28	35.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	31.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:8	43.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:28	5.9 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:8	35.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:28	58.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:8	17.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:8	88.2 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:28	29.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:28	59.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:8	84.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	65.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:8	88.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	67.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:8	65.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:28	49.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:28	65.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:28	14.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenA >=1:8	28.6 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:28	19.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:8	81.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenC >=1:28	66.7 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenY >=1:8	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	23.8 percentage of participants

Primary

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 7 years after primary vaccination (Year 2 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:8	58.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:8	78.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	26.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:8	35.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:28	21.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:28	61.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	23.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:28	33.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:28	52.4 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:28	9.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:8	71.4 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:28	28.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	9.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:8	28.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	9.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:8	9.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	69.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	73.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:8	75.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:28	44.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:28	61.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:28	69.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:8	74.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:8	84.2 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	11.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:8	14.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:8	81.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:8	18.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenA: >=1:28	11.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenY: >=1:28	14.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	7.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination	rSBA-MenC: >=1:28	66.7 percentage of participants

Primary

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 8 years after primary vaccination (Year 3 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:8	78.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	27.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	29.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:8	40.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:8	47.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:28	38.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:28	64.6 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:28	23.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	13.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:8	4.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:8	77.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:8	40.9 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:28	4.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:28	50.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	9.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:28	40.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:8	70.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:28	73.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	76.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:28	45.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:8	85.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:28	61.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:8	79.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	76.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:8	24.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:28	12.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenY: >=1:28	20.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:28	64.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	20.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenC: >=1:8	88.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	20.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination	rSBA-MenA: >=1:8	24.0 percentage of participants

Primary

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 9 years after primary vaccination (Year 4 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:28	65.6 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	32.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:8	42.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:28	34.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:8	67.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	26.6 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:8	81.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:28	31.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:28	38.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	9.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	9.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:28	4.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:28	57.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:8	4.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:8	47.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:8	85.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:8	66.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	71.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:28	58.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:8	79.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:28	64.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:8	86.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:28	57.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	76.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:28	16.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:28	16.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:28	68.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:28	16.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenA >=1:8	24.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenC >=1:8	84.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenW-135 >=1:8	16.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination	rSBA-MenY >=1:8	20.0 percentage of participants

Primary

Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination

Serogroups included Neisseria meningitidis serogroup A (MenA), Neisseria meningitidis serogroup C (MenC), Neisseria meningitidis serogroup W-135 (MenW-135) and Neisseria meningitidis serogroup Y (MenY).

Time frame: 6 years after primary vaccination (Year 1 of study MENACWY-TT-100)

Population: All eligible participants who received primary vaccination with MenACWY-TT, Meningitec, or Mencevax ACWY during study MenACWY-TT-027 and had available assay results for at least 1 tested antigen. Here, Overall Number of Participants Analyzed (N) signifies number of participants evaluable for this measure.

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:8	51.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:8	77.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	33.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:8	38.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:28	16.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:28	70.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	29.6 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:28	33.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:28	56.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:28	6.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:8	75.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:28	31.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	6.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:8	37.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	12.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:8	18.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	73.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	73.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:8	71.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:28	55.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:28	68.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:28	65.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:8	79.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:8	82.7 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:8	12.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:8	20.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:8	79.2 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:8	12.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenA: >=1:28	8.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenY: >=1:28	20.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenW-135: >=1:28	12.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination	rSBA-MenC: >=1:28	62.5 percentage of participants

Secondary

Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)

Population: All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in this study (MenACWY-TT-100) and had available assay results for the 1 month post booster vaccination blood sample. N: number of participants evaluable for this measure.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenY	7660.5 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenC	7163.5 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenW-135	25911.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenA	5122.3 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenC	5792.6 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenY	6316.9 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenW-135	17970.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenA	4871.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenW-135	27944.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenC	4020.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenA	4626.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenY	7529.7 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenY	6959.2 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenC	15101.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenW-135	10462.5 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination	rSBA-MenA	6414.2 titers

Secondary

Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)

Population: All eligible participants: received primary vaccination in study MenACWY-TT-027, booster vaccination in study MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. N: number of participants evaluable for this measure. Number analyzed: participants analyzed for specified serogroup titers cut off.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC	33959.8 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY	12154.3 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA	1534.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135	11924.8 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA	90.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC	42559.2 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY	407.8 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135	258.1 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA	1213.0 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY	11127.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC	15543.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135	6965.2 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA	211.1 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY	453.9 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135	199.6 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC	44794.4 titers

Secondary

Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY. hSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: hSBA antibody titer \>= 1:8 one month after vaccination, and at least 4-fold increase in hSBA titers one month after vaccination.

Time frame: 1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenA	98.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenY	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenW-135	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenC	86.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenC	92.9 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenW-135	90.9 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenA	93.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenY	71.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenC	85.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenA	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenW-135	96.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenY	98.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenC	94.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenA	88.2 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenY	78.6 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination	hSBA-MenW-135	100.0 percentage of participants

Secondary

Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:4	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:4	87.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:4	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:4	93.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:8	87.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:8	93.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:4	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:4	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:4	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:4	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:4	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:8	94.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenY: >=1:8	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenC: >=1:4	94.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenA: >=1:8	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	hSBA-MenW-135: >=1:8	100.0 percentage of participants

Secondary

Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination

New onset chronic illness included autoimmune disorders, asthma, type I diabetes, allergies.

Time frame: Up to 6 months post booster vaccination

Population: Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.

Arm	Measure	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination	1.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination	4.8 percentage of participants

Secondary

Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY. rSBA booster response to meningococcal antigens (A,C, W-135 and Y) is defined as: rSBA antibody titer \>= 1:32 one month after vaccination, and at least 4-fold increase in rSBA titers one month after vaccination.

Time frame: 1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)

Population: All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in this study (MenACWY-TT-100), had available assay results for 1 month post booster vaccination blood sample. N: number of participants evaluable for this measure. Number analyzed: participants analyzed for specified serogroup.

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenW-135	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenA	90.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenY	95.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenC	82.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenA	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenW-135	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenC	93.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenY	87.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenC	75.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenW-135	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenA	87.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenY	93.2 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenA	94.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenW-135	88.2 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenY	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination	rSBA-MenC	94.1 percentage of participants

Secondary

Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 1 month after booster vaccination (approximately Year 5.5 of study MENACWY-TT-100)

Population: All eligible participants who received primary vaccination in study MenACWY-TT-027 and booster vaccination in MenACWY-TT-100, had available assay results for 1 month post booster vaccination blood sample. N: number of participants evaluable for this measure. Number analyzed: participants analyzed for specified serogroup titers cut off.

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:28	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:28	98.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:8	98.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:8	98.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:28	98.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:28	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:28	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:28	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:28	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:28	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:28	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:8	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:28	95.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:28	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:28	100.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:8	95.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:8	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:28	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenY >= 1:8	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:8	94.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:28	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenA: >= 1:8	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenW-135: >= 1:28	94.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination	rSBA-MenC: >= 1:28	100.0 percentage of participants

Secondary

Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination

An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame: Up to 6 months post booster vaccination

Population: Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.

Arm	Measure	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination	1.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination	0.0 percentage of participants

Secondary

Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination

Solicited general events: fatigue, gastrointestinal (GI) events (nausea, vomiting, diarrhea and/or abdominal pain, headache (0= normal, 1=mild/easily tolerated, 2=moderate/interfered with normal activity, 3=severe/prevented normal activity) and fever (\>=37.5°C for oral/axillary/tympanic route, \>=38.0°C for rectal route). Solicited local events: pain (0=none, 1=mild, not interfered/prevented normal activity, 2=moderate, painful when limb moved/interfered with normal activity, 3=severe, significant pain at rest/prevented normal activity), redness and swelling at injection site (record greatest surface diameter in millimeter (mm) as 0 to \<=20 mm, \>20 to \<=50 mm, \>50 mm). Participants may be represented in more than 1 category. Only categories with at least 1 participant reported. 'Medical advice' signifies medical advice received to resolve any event. 'Related'=relationship to study vaccine assessed by investigator.

Time frame: Up to 4 days post booster vaccination

Population: Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage. Number analyzed: participants analyzed for specified category.

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All headache	20.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >20 to <=50 mm	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 2	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 1	7.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >50 mm	6.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3 related	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fever	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All swelling	17.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3 Related	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3 related	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: 0 to <=20 mm	14.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3 related	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Related	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Related	17.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >20 to <=50 mm	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 1	14.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 1	43.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Related	7.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >50 mm	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 2	6.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All gastrointestinal event (GI)	9.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 1	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fatigue	31.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Related fatigue	31.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All redness	35.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 1	20.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Severe pain: Grade 3	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Medical advice	0.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: 0 to <=20 mm	28.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 2	9.0 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 2	16.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 2	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3	1.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All pain	59.7 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 1	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Related fatigue	12.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3 Related	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 2	18.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All gastrointestinal event (GI)	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fever	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 1	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 1	18.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 2	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3 related	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All pain	56.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Severe pain: Grade 3	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3 related	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All headache	31.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: 0 to <=20 mm	25.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >20 to <=50 mm	18.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All redness	43.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >50 mm	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3 related	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All swelling	6.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Related	31.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: 0 to <=20 mm	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Medical advice	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Related	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >20 to <=50 mm	6.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >50 mm	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 1	37.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fatigue	12.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Related	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 1	12.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 2	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 2	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 2	12.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: 0 to <=20 mm	31.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All pain	59.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 2	16.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 2	6.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3 related	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Related	17.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3 related	1.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 1	40.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Severe pain: Grade 3	2.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All redness	36.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >20 to <=50 mm	2.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >50 mm	2.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All swelling	23.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: 0 to <=20 mm	16.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >20 to <=50 mm	1.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >50 mm	5.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fatigue	29.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 1	16.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3	6.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Related fatigue	29.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3 Related	6.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fever	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 1	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 2	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Related	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All gastrointestinal event (GI)	17.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 1	13.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 2	2.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3	1.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All headache	27.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 1	18.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 2	6.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3	1.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Related	24.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3 related	1.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Medical advice	1.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 1	4.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 2	9.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 1	14.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All pain	61.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 2	9.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fatigue	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >50 mm	9.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Related	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: >20 to <=50 mm	4.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Swelling: 0 to <=20 mm	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Related	14.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All swelling	14.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >50 mm	9.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3 related	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: 0 to <=20 mm	14.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Severe pain: Grade 3	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All redness	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3 related	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 2	19.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 1	19.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All headache	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	GI: Grade 3	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Medical advice	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 2	4.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 1	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Pain: Grade 1	42.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Related	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 2	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fever: Grade 3 related	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All fever	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3 Related	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Headache: Grade 3	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	All gastrointestinal event (GI)	14.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Related fatigue	23.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Fatigue: Grade 3	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination	Redness: >20 to <=50 mm	0.0 percentage of participants

Secondary

Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination

An AE was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame: Up to 31 days post booster vaccination

Population: Analysis population included all participants who received a booster dose of study vaccine MenACWY-TT in the booster stage.

Arm	Measure	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination	23.9 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination	31.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination	35.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination	52.4 percentage of participants

Secondary

Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenW-135	8.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenY	7.3 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenC	378.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenA	4.8 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenC	362.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenW-135	19.5 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenW-135	7.6 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenA	4.2 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenW-135	8.5 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenY	8.6 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenY	15.8 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenC	542.5 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenA	3.8 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenC	319.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenW-135	31.8 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenC	368.1 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenY	11.6 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenA	5.0 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenY	7.9 titers
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA	4.7 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenC	217.2 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenW-135	3.8 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenC	112.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA	3.5 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenW-135	3.3 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenW-135	4.9 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenW-135	3.7 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenW-135	4.1 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenY	8.7 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenA	2.8 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenC	203.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenA	3.7 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenA	3.4 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenY	6.9 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenA	3.1 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenC	230.0 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenY	8.5 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenY	3.1 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenC	223.6 titers
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenY	5.8 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenY	54.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenC	365.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenW-135	62.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenY	36.8 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA	6.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenA	4.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenA	4.6 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenA	6.6 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenA	4.6 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenC	427.2 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenC	342.7 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenC	190.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenC	199.3 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenW-135	50.5 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenW-135	20.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenW-135	23.1 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenW-135	17.4 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenY	40.3 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenY	43.7 titers
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenY	35.5 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenC	125.7 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenC	273.8 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenW-135	4.2 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenC	169.2 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenC	234.8 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenY	13.9 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenY	7.3 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenA	5.4 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenA	4.5 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenA	6.7 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenY	10.5 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenA	4.7 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA	5.9 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenY	6.2 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenY	8.8 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-100: hSBA-MenW-135	3.3 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-100: hSBA-MenW-135	4.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenW-135	7.0 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-100: hSBA-MenW-135	2.8 titers
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-100: hSBA-MenC	119.1 titers

Secondary

Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs related to lack of vaccine efficacy were as judged by the investigator.

Time frame: Through 5 years (6, 7, 8, 9 and 10 years post primary vaccination)

Population: All the participants enrolled in the study.

Arm	Measure	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy	0.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy	0.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy	0.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy	0.0 percentage of participants

Secondary

Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination

Serogroups included MenA, MenC, MenW-135 and MenY.

Time frame: 6, 7, 8, 9 and 10 years after primary vaccination (Year 1, 2, 3, 4 and 5 of study MENACWY-TT-100)

Arm	Measure	Group	Value (NUMBER)
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC >=1:4	92.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenA>=1:8	31.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY>=1:4	41.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	44.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY>=1:4	32.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY>=1:4	50.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC >=1:4	91.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC >=1:4	90.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY>=1:4	51.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY>=1:4	31.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	70.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	44.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	44.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	44.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	39.1 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA >=1:4	34.1 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	60.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	39.1 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	60.3 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA >=1:4	26.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY >=1:8	41.4 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	70.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC>=1:8	91.9 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA >=1:4	32.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY >=1:8	32.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC>=1:8	90.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC>=1:8	92.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA >=1:4	39.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA >=1:4	31.1 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY >=1:8	50.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC>=1:8	89.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC>=1:8	92.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC >=1:4	92.5 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY >=1:8	51.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA>=1:8	26.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA>=1:8	30.2 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC >=1:4	89.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY >=1:8	31.7 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA>=1:8	32.8 percentage of participants
MenACWY-TT Vaccine: Less Than (<) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA>=1:8	25.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC >=1:4	95.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	20.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	19.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY>=1:4	40.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA>=1:8	27.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA >=1:4	28.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA >=1:4	14.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA >=1:4	27.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA >=1:4	25.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC >=1:4	93.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC >=1:4	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA >=1:4	30.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC >=1:4	95.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC >=1:4	93.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	13.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	18.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	21.4 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY>=1:4	7.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY>=1:4	33.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY>=1:4	38.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY>=1:4	26.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenA>=1:8	28.6 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA>=1:8	14.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA>=1:8	20.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA>=1:8	18.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC>=1:8	93.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC>=1:8	100.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC>=1:8	95.5 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC>=1:8	95.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC>=1:8	93.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	13.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	20.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	19.0 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	18.8 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	21.4 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY >=1:8	7.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY >=1:8	33.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY >=1:8	38.1 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY >=1:8	26.3 percentage of participants
MenCCRM (Meningitec) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY >=1:8	40.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	68.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC >=1:4	89.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenA>=1:8	41.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY >=1:8	65.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA>=1:8	26.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC >=1:4	88.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA>=1:8	43.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC >=1:4	93.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA>=1:8	33.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA >=1:4	43.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC>=1:8	93.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA >=1:4	34.8 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY >=1:8	75.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC>=1:8	88.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC>=1:8	89.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA >=1:4	28.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	56.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC>=1:8	85.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC>=1:8	91.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA >=1:4	26.3 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY >=1:8	72.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	81.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	79.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA >=1:4	42.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	56.4 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA>=1:8	28.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY >=1:8	72.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	67.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	79.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	81.5 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY>=1:4	72.6 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	61.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY >=1:8	67.9 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY>=1:4	65.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC >=1:4	91.1 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	61.2 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY>=1:4	75.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY>=1:4	72.0 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC >=1:4	86.7 percentage of participants
MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY>=1:4	67.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC >=1:4	96.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY>=1:4	44.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	9.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY >=1:8	27.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY>=1:4	40.7 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenA>=1:8	33.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC >=1:4	92.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	30.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-100: hSBA-MenA >=1:4	42.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA>=1:8	23.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY >=1:8	34.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA>=1:8	36.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC >=1:4	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY >=1:8	25.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenY>=1:4	34.8 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA>=1:8	26.1 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	18.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	12.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenY>=1:4	27.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA>=1:8	28.6 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenA >=1:4	33.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenA >=1:4	30.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	26.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenC>=1:8	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	12.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC >=1:4	100.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC >=1:4	91.7 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenC>=1:8	92.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenA >=1:4	40.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenY >=1:8	40.7 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	26.3 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 3 of study MENACWY-TT-10: hSBA-MenC>=1:8	96.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	18.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenY>=1:4	25.0 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 1 of study MENACWY-TT-10: hSBA-MenW-135>=1:4	30.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenC>=1:8	91.7 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 2 of study MENACWY-TT-10: hSBA-MenA >=1:4	26.9 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenY >=1:8	44.4 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 4 of study MENACWY-TT-10: hSBA-MenW-135 >=1:8	9.5 percentage of participants
MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years	Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination	Year 5 of study MENACWY-TT-10: hSBA-MenC>=1:8	100.0 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 10 Years of Primary Vaccination

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 6 Years of Primary Vaccination

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 7 Years of Primary Vaccination

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 8 Years of Primary Vaccination

Persistence Phase: Geometric Mean Titers as Measured by rSBA for Each of the 4 Serogroups After 9 Years of Primary Vaccination

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 10 Years of Primary Vaccination

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 7 Years of Primary Vaccination

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 8 Years of Primary Vaccination

Persistence Phase: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128 For Each of the 4 Serogroups After 9 Years of Primary Vaccination

Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination

Booster Phase: Geometric Mean Titers as Measured by rSBA For Each of the 4 Serogroups 1 Month After Booster Vaccination

Booster Phase: Geometric Mean Titers Using hSBA For Each of the 4 Serogroups at 1 Month After Booster Vaccination

Booster Phase: Percentage of Participants With hSBA Booster Response at 1 Month After Booster Vaccination

Booster Phase: Percentage of Participants With hSBA Titers >=1:4 and >=1:8 For Each of the 4 Serogroups at 1 Month After Booster Vaccination

Booster Phase: Percentage of Participants With New Onset Chronic Illness Up to 6 Months Post Booster Vaccination

Booster Phase: Percentage of Participants With rSBA Booster Response at 1 Month After Booster Vaccination

Booster Phase: Percentage of Participants With rSBA Titers >=1:8 and >=1:128 For Each of the 4 Serogroups at 1 Month After Booster Vaccination

Booster Phase: Percentage of Participants With Serious Adverse Events (SAEs) Up to 6 Months Post Booster Vaccination

Booster Phase: Percentage of Participants With Solicited Local and General Adverse Events up to 4 Days Post Booster Vaccination

Booster Phase: Percentage of Participants With Unsolicited Adverse Events up to 31 Days Post Booster Vaccination

Persistence Phase: Geometric Mean Titers as Measured by hSBA for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination

Persistence Phase: Percentage of Participants With Serious Adverse Events (SAEs) Related to Vaccination or Any Adverse Event (AE) Related to Lack of Vaccine Efficacy

Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >=1:4 and >=1:8 for Each of the 4 Serogroups After 6, 7, 8, 9 and 10 Years of Primary Vaccination